Tearsheet

Editas Medicine (EDIT)

Market Price (9/17/2025): $2.83 | Market Cap: $238.9 Mil
Sector: Health Care | Industry: Biotechnology

Editas Medicine (EDIT)

Market Price (9/17/2025): $2.83
Market Cap: $238.9 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -66%	Weak multi-year price returns 2Y Excs Rtn is -117%, 3Y Excs Rtn is -145%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -161 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -413%
1			Stock price has recently run up significantly 6M Rtn6 month market price return is 115%
2			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -42%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -518%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -527%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -104%
5			High stock price volatility Vol 12M is 137%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -66%
1	Weak multi-year price returns 2Y Excs Rtn is -117%, 3Y Excs Rtn is -145%
2	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -161 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -413%
3	Stock price has recently run up significantly 6M Rtn6 month market price return is 115%
4	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -42%
5	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -518%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -527%
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -104%
7	High stock price volatility Vol 12M is 137%

Market Valuation

	9/17/25	2024	2023	2022	2021
Share Price CYE	$2.83	$1.27	$10.13	$8.87	$26.55
Market Cap CYE ($ Mil)	238.9	104.9	828.4	610.2	1,815.1
Total Debt ($ Mil)	21.1	35.0	36.5	43.9	26.4
Total Cash ($ Mil)	178.5	269.9	323.1	344.3	499.8
Enterprise Value ($ Mil)	81.5	139.9	864.9	654.1	1,841.5
Valuation Ratios
P/S TTM	6.1	3.2	9.8	30.9	70.3
P/EBIT TTM	-1.1	-0.4	-4.5	-2.7	-9.3
P/E TTM	-1.0	-0.4	-5.0	-2.8	-9.3
Sector Ratios
P/S TTM (Sector)	3.7	3.6	4.1	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.9
P/E TTM (Sector)	-1.8	-1.5	-1.5	-1.3	-2.9

	9/17/25	2024	2023
Share Price CYE	$2.83	$1.27	$10.13
Market Cap CYE ($ Mil)	238.9	104.9	828.4
Total Debt ($ Mil)	21.1	35.0	36.5
Total Cash ($ Mil)	178.5	269.9	323.1
Enterprise Value ($ Mil)	81.5	139.9	864.9
Valuation Ratios
P/S TTM	6.1	3.2	9.8
P/EBIT TTM	-1.1	-0.4	-4.5
P/E TTM	-1.0	-0.4	-5.0
Sector Ratios
P/S TTM (Sector)	3.7	3.6	4.1
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-1.8	-1.5	-1.5

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
EDIT Return	137%	-62%	-67%	14%	-87%	123%	-91%
Peers Return	60%	35%	6%	8%	-6%	11%	156%
S&P 500 Return	16%	27%	-19%	24%	23%	12%	104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: NTLA, ABBV, AMGN, GILD, VRTX. See EDIT Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Better Bets than Editas Medicine (EDIT)

	EDIT	Better Performance than EDIT
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	-42.0%	ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (5.4%)
Rev Chg 3Y Avg	55.3%	BBIO (1225.0%), RYTM (137.5%), CYTK (824.6%), AXSM (699.5%), CRSP (380.7%)
Op Mgn LTM	-413.4%	ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM	-517.6%	ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM	-526.8%	ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield	-99.2%	ABBV (3.9%), AMGN (7.9%), GILD (7.4%), VRTX (3.6%), REGN (7.7%)

	EDIT	Better Performance than EDIT
Metric	Value	Sector (Health Care)
Rev Chg LTM	-42.0%	LLY (36.8%), JNJ (4.7%), ABBV (6.1%), UNH (9.7%), ABT (5.9%)
Rev Chg 3Y Avg	55.3%	HIMS (76.3%), BBIO (1225.0%), RYTM (137.5%), CYTK (824.6%), AXSM (699.5%)
Op Mgn LTM	-413.4%	LLY (43.0%), JNJ (24.5%), ABBV (23.5%), UNH (7.3%), ABT (17.4%)
CFO/Rev LTM	-517.6%	LLY (20.5%), JNJ (25.4%), ABBV (33.1%), UNH (6.8%), ABT (21.0%)
FCF/Rev LTM	-526.8%	LLY (-0.1%), JNJ (18.1%), ABBV (31.3%), UNH (6.0%), ABT (15.7%)
Total Yield	-99.2%	LLY (2.7%), JNJ (8.2%), ABBV (3.9%), UNH (9.4%), ABT (7.8%)

	EDIT	Better Performance than EDIT
Metric	Value	All Other Sectors
Rev Chg LTM	-42.0%	NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg	55.3%	NVDA (92.0%), RCL (65.4%), APO (129.8%), NU (70.1%), CCL (81.1%)
Op Mgn LTM	-413.4%	NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM	-517.6%	NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM	-526.8%	NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield	-99.2%	NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.8%)

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Editas Medicine (EDIT) Stock: 35% of days in last 3 months had 1% or greater fluctuation
2	Editas Medicine Market Price	Market Price
3	Day 5 of Gains Streak for Editas Medicine Stock with 171% Return (vs. 152% YTD) [2/20/2025]	Notification
4	Day 1 of Loss Streak for Editas Medicine Stock with -1.2% Return (vs. -66% YTD) [10/17/2024]	Notification
5	Editas Medicine vs. S&P500 Correlation	Correlation
6	Editas Medicine Price Volatility	Volatility
7	Day 8 of Gains Streak for Editas Medicine Stock with 10% Return (vs. 1.1% YTD) [7/12/2023]	Notification
8	Day 6 of Loss Streak for Editas Medicine Stock with -30% Return (vs. -10% YTD) [6/22/2023]	Notification
9	Day 5 of Loss Streak for Editas Medicine Stock with -31% Return (vs. -11% YTD) [6/21/2023]	Notification
10	Editas Medicine (EDIT) Stock Has 49% Chance Of Rise In The Next One Month	Chance of Rise
11	ARTICLES
12	The Sell Off In Gene Editing Stocks Continues. Time To Buy?		February 8th, 2022
13	Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?		December 22nd, 2021
14	Is The Selling In Editas Stock Overdone?		September 30th, 2021
15	Will The Rally In Editas Stock Continue After A 20% Rise In A Month?		August 10th, 2021
16	Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?		March 5th, 2021

	Title
0	DASHBOARDS
1	The Sell Off In Gene Editing Stocks Continues. Time To Buy?
2	Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?
3	Is The Selling In Editas Stock Overdone?
4	Will The Rally In Editas Stock Continue After A 20% Rise In A Month?
5	Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?
6	ARTICLES
7	Editas Medicine (EDIT) Stock: 35% of days in last 3 months had 1% or greater fluctuation
8	Editas Medicine Market Price
9	Day 5 of Gains Streak for Editas Medicine Stock with 171% Return (vs. 152% YTD) [2/20/2025]
10	Day 1 of Loss Streak for Editas Medicine Stock with -1.2% Return (vs. -66% YTD) [10/17/2024]
11	Editas Medicine vs. S&P500 Correlation
12	Editas Medicine Price Volatility
13	Day 8 of Gains Streak for Editas Medicine Stock with 10% Return (vs. 1.1% YTD) [7/12/2023]
14	Day 6 of Loss Streak for Editas Medicine Stock with -30% Return (vs. -10% YTD) [6/22/2023]
15	Day 5 of Loss Streak for Editas Medicine Stock with -31% Return (vs. -11% YTD) [6/21/2023]
16	Editas Medicine (EDIT) Stock Has 49% Chance Of Rise In The Next One Month

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FGI	FGI Industries	139.3%	145.2%
2	CODX	Co-Diagnostics	80.8%	-14.8%
3	CNFR	Conifer	55.5%	50.4%
4	BGI	Birks	55.4%	-18.1%
5	FLUX	Flux Power	52.2%	99.4%
6	BOXL	Boxlight	45.7%	32.1%
7	LVRO	Lavoro	45.5%	-57.4%
8	NFE	New Fortress Energy	44.9%	-86.8%
9	WBTN	Webtoon Entertainment	39.0%	53.2%
10	HCWC	Healthy Choice Wellness	37.5%	-34.7%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	REX	REX American Resources	-50.1%	46.1%
2	XAGE	Longevity Health	-39.3%	-86.1%
3	BNGO	Bionano Genomics	-35.7%	-89.7%
4	IHT	InnSuites Hospitality Trust	-30.7%	7.3%
5	LUD	Luda Technology	-28.6%
6	NAOV	NanoVibronix	-28.5%	-88.2%
7	GDC	GD Culture	-28.2%	269.8%
8	ASST	Strive	-28.0%	813.4%
9	BIAF	bioAffinity Technologies	-25.5%	-71.3%
10	FAAS	DigiAsia	-23.9%	-87.2%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	BDSX	Biodesix	1313.2%	-78.6%
2	CLSD	Clearside Biomedical	954.0%	-74.9%
3	SDOT	Sadot	624.1%	-79.4%
4	WLDS	Wearable Devices	498.0%	-30.0%
5	CHEK	Check-Cap	285.6%	154.6%
6	ATCH	AtlasClear	275.9%	-91.0%
7	HSDT	Helius Medical Technologies	262.5%	-95.6%
8	OPI	Office Properties Income Trust	261.7%	-13.4%
9	FGI	FGI Industries	156.8%	145.2%
10	AIRE	ReAlpha Tech	154.0%	-56.1%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	NAKA	Kindly MD	-81.4%
2	ATYR	aTyr Pharma	-79.7%	-70.2%
3	LGCL	Lucas GC	-73.6%	-77.1%
4	EPSM	Epsium Enterprise	-70.1%
5	BNGO	Bionano Genomics	-59.4%	-89.7%
6	FAAS	DigiAsia	-58.5%	-87.2%
7	QMMM	QMMM	-57.5%	6775.0%
8	VCIG	VCI Global	-56.9%	-99.1%
9	YYGH	YY	-56.6%	-78.5%
10	XAGE	Longevity Health	-55.5%	-86.1%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	11963.5%	11963.5%
2	GIBO	GIBO	9734.4%
3	CHSN	Chanson International	7565.0%	-99.3%
4	LNZA	LanzaTech Global	7287.5%	-86.0%
5	QMMM	QMMM	3031.7%	6775.0%
6	OESX	Orion Energy Systems	1497.9%	22.9%
7	CURX	Curanex Pharmaceuticals	1401.6%	1401.6%
8	ENTO	Entero Therapeutics	565.6%	117.6%
9	PTNM	Pitanium	553.2%
10	WLDS	Wearable Devices	449.5%	-30.0%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	CJET	Chijet Motor	-92.2%	-95.0%
2	STFS	Star Fashion Culture	-92.2%	-97.8%
3	ELPW	Elong Power	-91.6%	-76.7%
4	NXTT	Next Technology	-89.6%	-95.1%
5	NAKA	Kindly MD	-89.0%
6	BINI	Bollinger Innovations	-88.9%	-100.0%
7	JEM	707 Cayman	-88.4%	-98.2%
8	YAAS	Youxin Technology	-82.5%	-98.3%
9	NEON	Neonode	-82.0%	-50.2%
10	NVNO	enVVeno Medical	-81.5%	-69.8%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FGI	FGI Industries	139.3%	145.2%
2	CODX	Co-Diagnostics	80.8%	-14.8%
3	CNFR	Conifer	55.5%	50.4%
4	BGI	Birks	55.4%	-18.1%
5	FLUX	Flux Power	52.2%	99.4%
6	BOXL	Boxlight	45.7%	32.1%
7	LVRO	Lavoro	45.5%	-57.4%
8	NFE	New Fortress Energy	44.9%	-86.8%
9	WBTN	Webtoon Entertainment	39.0%	53.2%
10	HCWC	Healthy Choice Wellness	37.5%	-34.7%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	REX	REX American Resources	-50.1%	46.1%
2	XAGE	Longevity Health	-39.3%	-86.1%
3	BNGO	Bionano Genomics	-35.7%	-89.7%
4	IHT	InnSuites Hospitality Trust	-30.7%	7.3%
5	LUD	Luda Technology	-28.6%
6	NAOV	NanoVibronix	-28.5%	-88.2%
7	GDC	GD Culture	-28.2%	269.8%
8	ASST	Strive	-28.0%	813.4%
9	BIAF	bioAffinity Technologies	-25.5%	-71.3%
10	FAAS	DigiAsia	-23.9%	-87.2%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	BDSX	Biodesix	1313.2%	-78.6%
2	CLSD	Clearside Biomedical	954.0%	-74.9%
3	SDOT	Sadot	624.1%	-79.4%
4	WLDS	Wearable Devices	498.0%	-30.0%
5	CHEK	Check-Cap	285.6%	154.6%
6	ATCH	AtlasClear	275.9%	-91.0%
7	HSDT	Helius Medical Technologies	262.5%	-95.6%
8	OPI	Office Properties Income Trust	261.7%	-13.4%
9	FGI	FGI Industries	156.8%	145.2%
10	AIRE	ReAlpha Tech	154.0%	-56.1%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	NAKA	Kindly MD	-81.4%
2	ATYR	aTyr Pharma	-79.7%	-70.2%
3	LGCL	Lucas GC	-73.6%	-77.1%
4	EPSM	Epsium Enterprise	-70.1%
5	BNGO	Bionano Genomics	-59.4%	-89.7%
6	FAAS	DigiAsia	-58.5%	-87.2%
7	QMMM	QMMM	-57.5%	6775.0%
8	VCIG	VCI Global	-56.9%	-99.1%
9	YYGH	YY	-56.6%	-78.5%
10	XAGE	Longevity Health	-55.5%	-86.1%

Peer Comparisons for Editas Medicine

Financials

	EDIT	NTLA	ABBV	AMGN	GILD	VRTX	Median
Name	Editas M.	Intellia.	AbbVie	Amgen	Gilead S.	Vertex P.
Mkt Price	2.83	12.27	216.26	273.08	110.86	391.36	163.56
Mkt Cap	0.2	1.3	382.3	146.9	138.0	100.5	119.2
Rev LTM	39	53	58,328	34,917	28,862	11,419	20,140
Op Inc LTM	-161	-512	13,695	8,192	10,797	-199	4,016
FCF LTM	-205	-422	18,239	10,605	9,369	3,500	6,434
FCF 3Y Avg	-182	-396	20,273	8,590	8,397	1,984	5,191
CFO LTM	-201	-419	19,283	12,013	9,868	3,846	6,857
CFO 3Y Avg	-177	-387	21,154	9,753	8,949	2,324	5,636

Growth & Margins

	EDIT	NTLA	ABBV	AMGN	GILD	VRTX	Median
Name	Editas M.	Intellia.	AbbVie	Amgen	Gilead S.	Vertex P.
Rev Chg LTM	-42.0%	15.0%	6.1%	12.9%	3.8%	10.5%	8.3%
Rev Chg 3Y Avg	55.3%	6.2%	0.6%	10.0%	1.6%	11.0%	8.1%
Rev Chg Q	597.5%	104.8%	6.6%	9.4%	1.8%	12.1%	10.7%
QoQ Delta Rev Chg LTM	8.6%	16.0%	1.7%	2.3%	0.4%	2.9%	2.6%
Op Mgn LTM	-413.4%	-968.7%	23.5%	23.5%	37.4%	-1.7%	10.9%
Op Mgn 3Y Avg	-616.5%	-991.9%	27.2%	26.4%	39.2%	26.5%	26.5%
QoQ Delta Op Mgn LTM	164.9%	218.7%	1.0%	1.6%	-0.0%	2.0%	1.8%
CFO/Rev LTM	-517.6%	-791.9%	33.1%	34.4%	34.2%	33.7%	33.4%
CFO/Rev 3Y Avg	-538.7%	-766.0%	37.5%	32.0%	31.9%	22.5%	27.2%
FCF/Rev LTM	-526.8%	-798.0%	31.3%	30.4%	32.5%	30.6%	30.5%
FCF/Rev 3Y Avg	-552.8%	-785.0%	36.0%	28.2%	30.0%	19.2%	23.7%

Valuation

	EDIT	NTLA	ABBV	AMGN	GILD	VRTX	Median
Name	Editas M.	Intellia.	AbbVie	Amgen	Gilead S.	Vertex P.
Mkt Cap	0.2	1.3	382.3	146.9	138.0	100.5	119.2
P/S	6.1	24.1	6.6	4.2	4.8	8.8	6.3
P/EBIT	-1.1	-2.5	64.9	14.2	16.8	22.9	15.5
P/E	-1.0	-2.7	101.6	22.2	21.9	27.6	22.0
P/CFO	-1.2	-3.0	19.8	12.2	14.0	26.1	13.1
Total Yield	-99.2%	-37.7%	3.9%	7.9%	7.4%	3.6%	3.8%
Dividend Yield	0.0%	0.0%	3.0%	3.4%	2.9%	0.0%	1.4%
FCF Yield 3Y Avg	-61.3%	-23.9%	7.3%	6.2%	8.0%	2.1%	4.1%
D/E	0.1	0.1	0.2	0.4	0.2	0.0	0.1
Net D/E	-0.7	-0.3	0.2	0.3	0.1	-0.0	0.0

Returns

	EDIT	NTLA	ABBV	AMGN	GILD	VRTX	Median
Name	Editas M.	Intellia.	AbbVie	Amgen	Gilead S.	Vertex P.
1M Rtn	-6.6%	11.6%	4.6%	-7.9%	-5.7%	-0.4%	-3.0%
3M Rtn	32.2%	28.1%	17.6%	-5.1%	3.4%	-11.5%	10.5%
6M Rtn	115.2%	33.5%	2.9%	-12.8%	2.0%	-23.6%	2.5%
12M Rtn	-26.1%	-43.0%	14.4%	-15.8%	37.3%	-20.0%	-17.9%
3Y Rtn	-80.4%	-81.3%	68.0%	30.0%	88.1%	35.1%	32.5%
1M Excs Rtn	-9.0%	9.2%	2.2%	-10.3%	-8.1%	-2.8%	-5.5%
3M Excs Rtn	21.5%	27.4%	4.8%	-16.4%	-8.8%	-22.7%	-2.0%
6M Excs Rtn	84.3%	11.7%	-13.8%	-28.9%	-16.3%	-40.2%	-15.0%
12M Excs Rtn	-42.6%	-58.7%	-2.6%	-32.6%	20.5%	-36.3%	-34.4%
3Y Excs Rtn	-144.6%	-143.4%	8.7%	-41.1%	28.7%	-28.5%	-34.8%

Comparison Analyses

	Title
0	Editas Medicine vs CRISPR Therapeutics AG: Industry Peers; Which Stock Is A Better Bet?
1	Editas Medicine vs Intellia Therapeutics: Industry Peers; Which Stock Is A Better Bet?
2	Editas Medicine vs FuelCell Energy: Similar Revenue; Which Stock Is A Better Bet?
3	Editas Medicine vs Badger Meter: Similar Market Cap; Which Stock Is A Better Bet?
4	Editas Medicine vs Viavi Solutions: Similar Market Cap; Which Stock Is A Better Bet?
5	Editas Medicine vs Callaway Golf: Similar Market Cap; Which Stock Is A Better Bet?
6	Editas Medicine vs Progyny: Similar Market Cap; Which Stock Is A Better Bet?
7	Editas Medicine vs TeleTech: Similar Market Cap; Which Stock Is A Better Bet?
8	Editas Medicine vs Pacific Biosciences of California: Similar Revenue; Which Stock Is A Better Bet?

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/12/2025	3/5/2025	2/28/2024	2/22/2023	2/24/2022	2/26/2021	2/26/2020
Key Financials
Total Revenue	39	32	78	20	26	91	21
EBITDA	-218	-233	-163	-220	-188	-131	-138
Operating Income	-161	-239	-169	-226	-193	-135	-141
Net Income	-237	-237	-153	-220	-193	-116	-134
EPS	-2.85	-2.88	-2.02	-3.21	-2.85	-1.98	-2.68
Growth Rates
Total Revenue Growth	-42.0%	-58.6%	296.3%	-22.8%	-71.8%	341.9%	-35.7%
EBITDA Growth	-10.4%	-42.9%	25.7%	-16.8%	-43.7%	5.2%	-25.0%
Operating Income Growth	24.5%	-41.2%	25.1%	-17.0%	-43.2%	4.3%	-23.9%
Net Income Growth	-22.4%	-54.7%	30.5%	-14.5%	-66.0%	13.3%	-21.6%
Margins
EBITDA Margin	-561.4%	-721.4%	-208.8%	-1114.1%	-736.3%	-144.3%	-672.6%
Operating Income Margin	-413.4%	-739.4%	-216.6%	-1146.3%	-756.1%	-148.6%	-686.4%
Net Income Margin	-608.9%	-733.7%	-196.1%	-1118.3%	-753.6%	-127.8%	-651.4%
Cash & Debt
Total Cash	179	270	323	344	500	402	457
Total Debt	21	35	37	44	26	26	29
Net Debt / (Cash)	-157	-235	-287	-300	-473	-376	-428
Cash Flows
Net Cash from Operations	-201	-210	-132	-177	-164	-180	-41
Free Cash from Operations	-205	-219	-137	-181	-172	-187	-47
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/12/2025	5/12/2025	3/5/2025	11/4/2024	8/7/2024	5/8/2024	2/28/2024	11/3/2023	8/2/2023	5/5/2023	2/22/2023	11/2/2022
Key Financials Quarterly
Total Revenue	4	5	31	0	1	1	60	5	3	10	7	0
Ebitda	-49	-72	-33	-64	-66	-61	-22	-49	-43	-49	-62	-56
Operating Income	-25	-35	-34	-66	-72	-67	-24	-50	-44	-51	-63	-58
Net Income	-53	-76	-45	-62	-68	-62	-19	-45	-40	-49	-61	-56
EPS	-0.63	-0.92	-0.55	-0.75	-0.82	-0.76	-0.23	-0.55	-0.56	-0.71	-0.88	-0.81
Key Financials TTM
Total Revenue TTM	39	36	32	62	67	69	78	25	19	23	20	26
Ebitda TTM	-218	-235	-224	-213	-198	-174	-163	-202	-210	-220	-220	-198
Operating Income TTM	-161	-207	-239	-229	-213	-185	-169	-209	-216	-226	-226	-204
Net Income TTM	-237	-251	-237	-211	-193	-166	-153	-195	-206	-219	-220	-201
Growth Rates Quarterly
Total Revenue Growth	597.5%	310.4%	-49.0%	-98.9%	-82.2%	-88.5%	818.7%	12604.8%	-54.6%	45.5%	-47.6%	-99.3%
EBITDA Growth	25.4%	-18.9%	-46.6%	-31.7%	-55.5%	-22.5%	63.6%	13.0%	19.2%	-0.5%	-54.3%	-46.9%
Operating Income Growth	64.6%	47.3%	-43.4%	-30.9%	-63.1%	-31.5%	62.2%	12.8%	18.7%	-0.4%	-52.5%	-46.5%
Net Income Growth	21.3%	-22.8%	-140.5%	-38.0%	-67.8%	-26.3%	68.9%	19.2%	24.6%	2.9%	-46.6%	-42.6%
Margins Quarterly
EBITDA Margin	-1380.1%	-1544.8%	-107.8%	-105027.9%	-12901.9%	-5334.0%	-37.5%	-911.7%	-1474.0%	-501.6%	-946.6%	-133133.3%
Operating Income Margin	-711.6%	-758.1%	-112.3%	-107649.2%	-14016.2%	-5902.3%	-39.9%	-940.1%	-1527.3%	-517.3%	-970.7%	-136952.4%
Net Income Margin	-1487.8%	-1633.5%	-148.3%	-101870.5%	-13178.8%	-5458.1%	-31.4%	-843.7%	-1395.6%	-497.8%	-929.3%	-132681.0%
Cash & Debt
Total Cash	179	221	270	265	279	296	323	350	432	318	344	420
Total Debt	21	31	35	38	39	34	37	35	37	37	44	21
Net Debt / (Cash)	-157	-190	-235	-227	-240	-262	-287	-315	-395	-281	-300	-398
Cash Flows Quarterly
FCF from Operations	-50	-48	-51	-53	-57	-50	-22	-35	-39	-36	-42	-48
Cash Flows TTM
FCF from Operations TTM	-201	-208	-210	-182	-165	-146	-132	-152	-165	-164	-177	-170
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-7.0%	-10.0%	-10.0%	-19.1%	-21.3%	-20.2%	-7.4%	-16.0%	-15.0%	-17.5%	-22.3%	-22.3%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-11.0%	-14.6%	-17.5%	-16.7%	-15.7%	-14.0%	-13.1%	-16.6%	-18.4%	-19.4%	-19.8%	-19.7%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Business of developing and commercializing genome editing technology	78	20	26	91	21
Total	78	20	26	91	21

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$2.83
Market Cap ($ Bil)	0.2
First Trading Date	02/03/2016
Distance from 52W High	-27.6%
	50 Days	200 Days
DMA Price	$2.75	$1.89
DMA Trend	down	up
Distance from DMA	3.0%	49.9%
	3M	1YR
Volatility	112.9%	137.7%
Downside Capture	244.20	343.88
Upside Capture	265.56	259.65
Correlation (SPY)	19.7%	31.3%

EDIT Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.99	2.94	3.64	2.11	2.18	2.00
Up Beta	-0.75	-0.12	0.82	1.90	1.77	1.89
Down Beta	-0.01	0.99	4.01	1.49	1.40	1.61
Up Capture	302%	559%	657%	558%	759%	844%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	9	17	28	55	105	329
Down Capture	330%	478%	390%	189%	165%	109%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	12	24	33	67	139	407

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8292025
Short Interest: Shares Quantity	7,815,797
Short Interest: % Change Since 8152025	-4.7%
Average Daily Volume	1,073,735
Days-to-Cover Short Interest	7.28
Basic Shares Quantity	84,412,200
Short % of Basic Shares	9.3%

Returns Analyses

	Title
0	Editas Medicine Stock Return Comparison
1	[9/30/2021] Editas Medicine (EDIT) Stock Price Forecast: AI Forecasts EDIT Stock Price To Be Around $53.60 In A Month (Up 26%)
2	Editas Medicine (EDIT) Stock Return: AI Predicts EDIT Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/12/2025	34.5%	14.8%	18.3%
5/12/2025	-2.6%	-3.2%	31.8%
1/13/2025	-7.9%	-3.2%	-6.3%
10/22/2024	-12.5%	-13.3%	-34.0%
8/7/2024	-12.2%	-14.7%	-25.4%
5/8/2024	-11.4%	0.0%	-4.4%
2/28/2024	24.9%	3.2%	-16.0%
11/3/2023	18.2%	11.9%	57.2%
...
SUMMARY STATS
# Positive	13	12	10
# Negative	10	11	13
Median Positive	9.5%	9.4%	27.6%
Median Negative	-6.1%	-5.4%	-17.3%
Max Positive	34.5%	45.1%	58.3%
Max Negative	-12.5%	-15.9%	-34.0%

	Forward Returns
8/12/2025	34.5%	14.8%	18.3%
5/12/2025	-2.6%	-3.2%	31.8%
1/13/2025	-7.9%	-3.2%	-6.3%
10/22/2024	-12.5%	-13.3%	-34.0%
8/7/2024	-12.2%	-14.7%	-25.4%
5/8/2024	-11.4%	0.0%	-4.4%
2/28/2024	24.9%	3.2%	-16.0%
11/3/2023	18.2%	11.9%	57.2%
8/2/2023	5.7%	2.9%	4.5%
5/5/2023	12.0%	9.6%	8.3%
2/22/2023	6.2%	-1.5%	-20.5%
11/2/2022	1.1%	-12.0%	-21.1%
8/3/2022	13.4%	9.2%	-10.8%
2/24/2022	10.1%	19.0%	31.5%
11/8/2021	8.2%	1.1%	-17.4%
8/4/2021	9.4%	45.1%	58.3%
5/5/2021	0.2%	-5.4%	-3.8%
1/19/2021	-0.5%	-15.9%	-23.2%
11/5/2020	-3.4%	-11.9%	23.8%
8/6/2020	-5.8%	-4.1%	-17.3%
5/7/2020	-3.6%	-2.0%	6.6%
2/26/2020	-6.4%	2.7%	-6.3%
11/12/2019	9.5%	13.5%	45.1%
SUMMARY STATS
# Positive	13	12	10
# Negative	10	11	13
Median Positive	9.5%	9.4%	27.6%
Median Negative	-6.1%	-5.4%	-17.3%
Max Positive	34.5%	45.1%	58.3%
Max Negative	-12.5%	-15.9%	-34.0%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8122025	10-Q 6/30/2025
3312025	5122025	10-Q 3/31/2025
12312024	3052025	10-K 12/31/2024
9302024	11042024	10-Q 9/30/2024
6302024	8072024	10-Q 6/30/2024
3312024	5082024	10-Q 3/31/2024
12312023	2282024	10-K 12/31/2023
9302023	11032023	10-Q 9/30/2023
6302023	8022023	10-Q 6/30/2023
3312023	5052023	10-Q 3/31/2023
12312022	2222023	10-K 12/31/2022
9302022	11022022	10-Q 9/30/2022
6302022	8032022	10-Q 6/30/2022
3312022	5042022	10-Q 3/31/2022
12312021	2242022	10-K 12/31/2021
9302021	11092021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Parison Amy	SVP, Chief Financial Officer	8082025	Sell	2.58	679	1,752	43,414	Form
1	Parison Amy	SVP, Chief Financial Officer	6042025	Sell	1.72	446	769	30,180	Form
2	Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	6042025	Sell	1.72	726	1,252	119,872	Form
3	O'Neill Gilmore Neil	CEO	6042025	Sell	1.72	15,192	26,196	483,290	Form
4	Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	3052025	Sell	1.71	4,109	7,030	192,841	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Editas Medicine (EDIT)

Market Price (9/17/2025): $2.83 | Market Cap: $238.9 MilSector: Health Care | Industry: Biotechnology

Editas Medicine (EDIT)

Market Price (9/17/2025): $2.83Market Cap: $238.9 MilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Editas Medicine (EDIT)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Editas Medicine

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/17/2025): $2.83 | Market Cap: $238.9 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (9/17/2025): $2.83
Market Cap: $238.9 Mil
Sector: Health Care
Industry: Biotechnology